Obinutuzumab plus bendamustine

The combination of obinutuzumab and bendamustine is a therapeutic regimen used primarily in the treatment of certain types of blood cancers. Based on the search results, I can provide comprehensive information about this drug combination. ## Drug Information Obinutuzumab plus bendamustine is a combination therapy that brings together two distinct medications with complementary mechanisms of action. This regimen is primarily used in the treatment of certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia, particularly in cases where previous treatments have failed or the disease has relapsed[1][3]. The combination typically involves intravenous administration of both drugs according to specific dosing schedules. Bendamustine is usually given at 90 mg/m² on days 1 and 2 of each 28-day cycle, while obinutuzumab follows a more complex dosing schedule that may include 100 mg on day 1, 900 mg on day 2, and 1000 mg on days 8 and 15 of the first cycle, followed by 1000 mg on day 1 of subsequent cycles[7][10]. ## Mechanism of Action This combination leverages two distinct mechanisms: 1. **Obinutuzumab** is a type II CD20 monoclonal antibody that binds to the CD20 antigen on B-lymphocytes. Unlike rituximab (a type I CD20 antibody), obinutuzumab has higher induction of antibody-dependent cytotoxicity and a stronger direct cytotoxic effect[9]. It targets and destroys B-cells, including malignant ones. 2. **Bendamustine** functions as a bifunctional alkylating agent with unique properties. It contains a nitrogen mustard group that causes DNA damage through alkylation and cross-linking, as well as a benzimidazole ring that may contribute antimetabolite properties[6]. Compared to other alkylating agents, bendamustine creates more persistent DNA double-strand breaks and induces a specific type of DNA repair (base excision repair) that is more complex and time-consuming, enhancing its cytotoxic effects[6]. ## Clinical Efficacy The GABRIELL phase II study evaluated this combination in relapsed/refractory chronic lymphocytic leukemia, showing an overall response rate of 78.6% with a median progression-free survival of 26 months[1]. The study also found that patients who achieved undetectable measurable residual disease had significantly longer progression-free and overall survival[1]. For follicular lymphoma, particularly in rituximab-refractory patients, the combination followed by obinutuzumab maintenance has demonstrated improved efficacy compared to bendamustine monotherapy[3][5]. In mantle cell lymphoma (MCL), the combination has shown promising results with higher complete response rates compared to historical data for bendamustine plus rituximab[10]. ## Safety Profile Common adverse effects include: - Hematological toxicities: neutropenia (58.3%), thrombocytopenia (26.4%), and febrile neutropenia (11.1%)[1] - Infusion-related reactions, particularly during the first infusion[8] - Risk of progressive multifocal leukoencephalopathy (PML)[8] - Potential for hepatitis B virus reactivation[8] - Cardiac toxicity and tumor lysis syndrome[5] Premedication protocols are typically implemented to manage infusion-related reactions, including corticosteroids, antihistamines, and antipyretics[5][7]. ## Administration Protocol The administration typically follows a specific protocol with premedication to prevent infusion reactions. For example, patients may receive methylprednisolone, chlorphenamine, and paracetamol before obinutuzumab infusions, particularly during the first cycle[5][7]. The infusion rates are carefully controlled, especially for the first infusion, to minimize the risk of reactions[7]. This combination represents an important treatment option for patients with certain B-cell malignancies, particularly those who have failed prior therapies or have high-risk disease features.

Brand names

Ribomustin

Other names

bendamustine and obinutuzumabobinutuzumab plus bendamustine